Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study

被引：0
|
作者：
Ezinwanne Onuoha
Andrew D. Smith
Robert Cannon
Moh’d Khushman
Harrison Kim
机构：
[1] University of Alabama,Department of Biomedical Engineering
[2] University of Alabama,Department of Radiology
[3] University of Alabama,Department of Surgery
[4] University of Alabama,Department of Medicine
来源：
Journal of Gastrointestinal Cancer | 2023年 / 54卷
关键词：
Hepatocellular carcinoma; Perfusion; Atezolizumab; Bevacizumab; Immune therapy; Anti-angiogenic therapy; Therapy response assessment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：776 / 781
页数：5
相关论文
共 50 条
  • [31] Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma
    Matsui, Teppei
    Nagai, Hidenari
    Mukozu, Takanori
    Wakui, Noritaka
    Matsuda, Takahisa
    Igarashi, Yoshinori
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (06) : 1058 - 1066
  • [32] Treatment effect of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma aiming at curative conversion therapy
    Tomonari, Tetsu
    Tani, Joji
    Sato, Yasushi
    Tanaka, Hironori
    Taniguchi, Tatsuya
    Kawano, Yutaka
    Masaki, Tsutomu
    Takayama, Tetsuji
    ANNALS OF ONCOLOGY, 2023, 34 : S1399 - S1399
  • [33] A MACHINE LEARNING MODEL TO PREDICT THE TREATMENT RESPONSE OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Hur, Moon Haeng
    Kim, Bo Hyun
    Song, Byeong Geun
    Sinn, Dong Hyun
    Shin, Hyunjae
    Cho, Yuri
    Park, Youngsu
    Park, Jeayeon
    Ko, Yunmi
    Lee, Yun Bin
    Cho, Eun Ju
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Lee, Jeong-Hoon
    HEPATOLOGY, 2024, 80
  • [34] Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab plus Bevacizumab Treatment of Hepatocellular Carcinoma
    Zhu, Andrew X.
    Dayyani, Farshid
    Yen, Chia-Jui
    Ren, Zhenggang
    Bai, Yuxian
    Meng, Zhiqiang
    Pan, Hongming
    Dillon, Paul
    Mhatre, Shivani K.
    Gaillard, Vincent E.
    Hernandez, Sairy
    Kelley, Robin Kate
    Sangro, Bruno
    CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3537 - 3545
  • [35] Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
    Chon, Young Eun
    Cheon, Jaekyung
    Kim, Hyeyeong
    Kang, Beodeul
    Ha, Yeonjung
    Kim, Do Young
    Hwang, Seong Gyu
    Chon, Hong Jae
    Kim, Beom Kyung
    CANCER MEDICINE, 2023, 12 (03): : 2731 - 2738
  • [36] Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report
    Uchida, Keisuke
    Ozono, Yoshinori
    Uchiyama, Naomi
    Hatada, Hiroshi
    Nakamura, Kenichi
    Komaki, Yuri
    Iwakiri, Hisayoshi
    Hasuike, Satoru
    Nagata, Kenji
    Sato, Yuichiro
    Kawakami, Hiroshi
    MEDICINE, 2022, 101 (35) : E30486
  • [37] Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
    Ishihara, Nobuaki
    Komatsu, Shohei
    Yano, Yoshihiko
    Fujishima, Yoshimi
    Ishida, Jun
    Kido, Masahiro
    Gon, Hidetoshi
    Fukushima, Kenji
    Urade, Takeshi
    Yoshida, Toshihiko
    Tai, Kentaro
    Arai, Keisuke
    Yanagimoto, Hiroaki
    Toyama, Hirochika
    Matsuura, Takanori
    Tada, Toshifumi
    Kodama, Yuzo
    Fukumoto, Takumi
    ANTICANCER RESEARCH, 2025, 45 (01) : 251 - 260
  • [38] Fecal microbiota transplant combined with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab-interim analysis of the FAB-HCC phase II pilot study
    Pomej, Katharina
    Frick, Adrian
    Scheiner, Bernhard
    Balcar, Lorenz
    Pajancic, Larissa
    Klotz, Anton
    Regnat, Katharina
    Zinober, Kerstin
    Trauner, Michael
    Tamandl, Dietmar
    Gasche, Christoph
    Pinter, Matthias
    JOURNAL OF HEPATOLOGY, 2024, 80 : S436 - S437
  • [39] Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
    Ahmed, Faiza
    Onwumeh-Okwundu, Jennifer
    Yukselen, Zeynep
    Endaya Coronel, Maria-Kassandra
    Zaidi, Madiha
    Guntipalli, Prathima
    Garimella, Vamsi
    Gudapati, Sravya
    Mezidor, Marc Darlene
    Andrews, Kim
    Mouchli, Mohamad
    Shahini, Endrit
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 13 (11) : 1813 - 1832
  • [40] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Hongyu Gong
    Siew Chin Ong
    Fan Li
    Zhiying Weng
    Keying Zhao
    Zhengyou Jiang
    Cost Effectiveness and Resource Allocation, 21
12345